Breaking News Instant updates and real-time market news.

OPHT

Ophthotech

$43.57

-2.56 (-5.55%)

, REGN

Regeneron

$402.82

0.8 (0.20%)

06:04
10/04/16
10/04
06:04
10/04/16
06:04

Ophthotech price target raised to $110 from $95 at JPMorgan

JPMorgan analyst Anupam Rama raised his price target for Ophthotech to $110 from $95 citing the elimination of Regeneron (REGN) from the Wet age-related macular degeneration space following its trial failure. Ophthotech closed yesterday down $2.56 to $43.57. The stock is down 20% since last Friday amid mechanism concerns following Regeneron's phase 2 data, Rama tells investors in a research note. The analyst views the weakness in Ophthotech as a buying opportunity. There are important mechanistic differences between the company's Fovista and Regeneron's REGN2176-3, and early phase 1 data for Fovista "are comparatively more compelling," the analyst contends. He points out that the Phase 3 results with Fovista + Lucentis combination therapy are expected this quarter. The analyst keeps an Overweight rating on Ophthotech.

OPHT

Ophthotech

$43.57

-2.56 (-5.55%)

REGN

Regeneron

$402.82

0.8 (0.20%)

  • 30

    Oct

  • 29

    Mar

OPHT Ophthotech
$43.57

-2.56 (-5.55%)

04/27/16
LEHM
04/27/16
INITIATION
Target $85
LEHM
Overweight
Ophthotech initiated with an Overweight at Barclays
Barclays analyst Carter Gould started Ophthotech with an Overweight rating and $85 price target.
06/02/16
JPMS
06/02/16
UPGRADE
Target $84
JPMS
Overweight
Ophthotech upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Anupam Rama upgraded Ophthotech to Overweight saying the Fovista phase 3 Lucentis combination studies reading out in Q4 have a very high probability of success. The analyst's base case assumes a four-plus letter gain in visual acuity compared to Lucentis monotherapy, resulting in 55%-60% share upside. His "homerun scenario," or five-plus letter, results in 150% share upside. He raised his price target for Ophthotech shares to $84 from $60.
09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
09/30/16
COWN
09/30/16
NO CHANGE
Target $60
COWN
Outperform
Ophthotech price target lowered to $60 from $80 at Cowen
Cowen analyst Tyler Van Buren said that Regeneron's (REGN) Phase 2 data for aflibercept co-formulated with rinucumab is negative for the class of anti-PDGFs as a whole and lowered his price target on Ophthotech (OPHT) to $60 from $80 after lowering his view of the probability of the success of its own wet AMD treatment to 50%. However, if a 3-4 letter benefit if observed when the Phase III trials read out in December, upside of $80-$120 per share from current levels is still possible, said Van Buren, who keeps an Outperform rating on Ophthotech shares.
REGN Regeneron
$402.82

0.8 (0.20%)

08/05/16
BARD
08/05/16
DOWNGRADE
Target $448
BARD
Neutral
Regeneron downgraded to Neutral at Baird
As reported previously, Baird downgraded Regeneron to Neutral from Outperform. The firm sees risk that the company will not be able to beat earnings consensus over the 2017/18 time frame unless there is a 15-20% downward revision in consensus estimates. Baird lowered its price target to $448 from $505 on Regeneron shares.
09/21/16
RBCM
09/21/16
NO CHANGE
RBCM
Regeneron Fasinumab deal positive, says RBC Capital
After Teva (TEVA) agreed to partner with Regeneron (REGN) on its Fasinumab pain killer, RBC Capital analyst Adrian Butt says that the deal validates the "under the radar" drug. The analyst says that Regeneron could make "many future deals" if its pipeline remains productive. Butt writes that the terms of the deal are attractive for Regeneon, and the analyst keeps a $648 price target and Outperform rating on the stock.
09/21/16
ROTH
09/21/16
NO CHANGE
Target $520
ROTH
Buy
Teva deal important for Regeneron, says at Roth Capital
Roth Capital analyst Joseph Pantginis points out that Regeneron (REGN) has signed a global partnership for fasinumab with Teva (TEVA), which he sees as an important new partnership for the former both on the product development front as well as a significant next step for fasinumab and the anti-NGF class of drugs. The analyst believes Regeneron has solid growth prospects and upside potential, and reiterates a Buy rating and $520 price target on the shares.
10/03/16
ROTH
10/03/16
NO CHANGE
Target $520
ROTH
Buy
Regeneron has 'solid' growth prospects, upside potential, says Roth Capital
After Regeneron (REGN) and Sanofi (SNY) released positive results from their Dupixent Phase 3 trials, SOLO 1 and SOLO in patients with atopic dermatitis, Roth Capital analyst Joseph Pantginis notes that clinical studies of Dupixent for additional atopic and allergic diseases are progressing and says he believes Regeneron's shares are poised for upside on upcoming catalysts. Moreover, the analyst says Regeneron has "solid" growth prospects based on approved and late stage products, deep pipeline, expansion of indications for current products, strong partners, and strong cash management. He reiterates a Buy rating and $520 price target on Regeneron's shares.

TODAY'S FREE FLY STORIES

15:10
12/07/16
12/07
15:10
12/07/16
15:10
General news
U.S. consumer credit rose $16.0 B in October »

U.S. consumer credit rose…

COST

Costco

$151.01

-0.76 (-0.50%)

15:04
12/07/16
12/07
15:04
12/07/16
15:04
Options
Costco options imply 4.3% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCO

Columbus McKinnon

$27.59

1.07 (4.03%)

15:03
12/07/16
12/07
15:03
12/07/16
15:03
Downgrade
Columbus McKinnon rating change  »

Follow-up: Columbus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

OTTR

Otter Tail

$38.90

0.1 (0.26%)

15:01
12/07/16
12/07
15:01
12/07/16
15:01
Initiation
Otter Tail initiated  »

Otter Tail initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:01
12/07/16
12/07
15:01
12/07/16
15:01
General news
Consumer Credit data reported »

October Consumer Credit…

WDC

Western Digital

$63.85

1.76 (2.83%)

15:00
12/07/16
12/07
15:00
12/07/16
15:00
Options
Western Digital calls active as shares surge »

Western Digital calls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCO

Columbus McKinnon

$27.59

1.07 (4.03%)

14:59
12/07/16
12/07
14:59
12/07/16
14:59
Downgrade
Columbus McKinnon rating change  »

Columbus McKinnon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

HON

Honeywell

$116.25

3.18 (2.81%)

14:58
12/07/16
12/07
14:58
12/07/16
14:58
Hot Stocks
Trian declines to comment as Honeywell hits high of day »

Nelson Peltz's Trian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

  • 16

    Dec

  • 10

    Jan

HRB

H&R Block

$23.42

0.73 (3.22%)

14:55
12/07/16
12/07
14:55
12/07/16
14:55
Technical Analysis
H&R Block technical comments ahead of earnings news »

The shares have been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

APO

Apollo Global

$19.99

0.71 (3.68%)

, CS

Credit Suisse

$15.46

0.77 (5.24%)

14:54
12/07/16
12/07
14:54
12/07/16
14:54
Periodicals
Apollo-backed Warrior working with lenders on IPO for next year, Bloomberg says »

Apollo Global…

APO

Apollo Global

$19.99

0.71 (3.68%)

CS

Credit Suisse

$15.46

0.77 (5.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 14

    Dec

14:50
12/07/16
12/07
14:50
12/07/16
14:50
General news
Canada Capacity Utilization Preview »

Canada Capacity…

LULU

lululemon

$57.24

0.12 (0.21%)

14:49
12/07/16
12/07
14:49
12/07/16
14:49
Options
lululemon options imply 14.0% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Jan

14:45
12/07/16
12/07
14:45
12/07/16
14:45
General news
Canada Housing Starts Preview »

Canada Housing Starts…

14:45
12/07/16
12/07
14:45
12/07/16
14:45
General news
Consumer Credit to be reported at 15:00 »

October Consumer Credit…

14:45
12/07/16
12/07
14:45
12/07/16
14:45
General news
Breaking General news story  »

November Treasury STRIPS…

ATSG

Air Transport Services

$16.32

0.02 (0.12%)

14:42
12/07/16
12/07
14:42
12/07/16
14:42
Hot Stocks
Air Transport Services says preliminary injunction granted in labor matter »

Air Transport Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$190.01

-0.935 (-0.49%)

14:42
12/07/16
12/07
14:42
12/07/16
14:42
Hot Stocks
Allergan CEO: Drug industry should self-regulate pricing »

Allergan CEO Brent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

COST

Costco

$151.01

-0.76 (-0.50%)

, HRB

H&R Block

$23.44

0.75 (3.31%)

14:40
12/07/16
12/07
14:40
12/07/16
14:40
Earnings
Notable companies reporting after market close »

Notable companies…

COST

Costco

$151.01

-0.76 (-0.50%)

HRB

H&R Block

$23.44

0.75 (3.31%)

LULU

lululemon

$57.24

0.12 (0.21%)

CAS

A. M. Castle

UNFI

United Natural Foods

$48.66

-0.7 (-1.42%)

VRNT

Verint

$38.20

0.15 (0.39%)

OLLI

Ollie's Bargain Outlet

$31.50

0.05 (0.16%)

TLRD

Tailored Brands

$18.89

0.58 (3.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 08

    Dec

  • 13

    Dec

  • 15

    Dec

  • 09

    Jan

  • 09

    Jan

HLT

Hilton

$26.81

0.495 (1.88%)

14:40
12/07/16
12/07
14:40
12/07/16
14:40
Options
Heightened call activity in Hilton everyday so far in December »

Heightened call activity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

TST

TheStreet

14:36
12/07/16
12/07
14:36
12/07/16
14:36
Initiation
TheStreet initiated  »

TheStreet initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

SYK

Stryker

$112.97

0.38 (0.34%)

14:34
12/07/16
12/07
14:34
12/07/16
14:34
Hot Stocks
Stryker raises quarterly dividend to 42.5c per share »

Stryker announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

VNCE

Vince Holding

$4.28

0.075 (1.79%)

14:30
12/07/16
12/07
14:30
12/07/16
14:30
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Jan

CMA

Comerica

$67.49

-0.2 (-0.30%)

14:30
12/07/16
12/07
14:30
12/07/16
14:30
Periodicals
Comerica moves higher as company alleged to 'warm' to possible sale »

According to Benzinga, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

CX

CEMEX

$8.42

0.205 (2.50%)

14:25
12/07/16
12/07
14:25
12/07/16
14:25
Options
Cemex call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:25
12/07/16
12/07
14:25
12/07/16
14:25
Conference/Events
Senate Commerce, Science & Transportation Committee to hold a hearing »

The Subcommittee on…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.